Aspire Biopharma Holdings Inc Financials
Financial Health Signals
Aspire Biopharma Holdings Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Aspire Biopharma Holdings Inc generates $0.16 in operating cash flow (-$2.1M OCF vs -$12.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Aspire Biopharma Holdings Inc (ASBPW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Aspire Biopharma Holdings Inc reported -$12.5M in net income in fiscal year 2024. This represents a decrease of 380.9% from the prior year.
Aspire Biopharma Holdings Inc held $4K in cash against $0 in long-term debt as of fiscal year 2024.
Aspire Biopharma Holdings Inc had 28M shares outstanding in fiscal year 2024.
Aspire Biopharma Holdings Inc spent $13.8M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 95.2% from the prior year.
ASBPW Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $1K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $884 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $208K+2870.0% | $7K | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $513K+167.8% | $192K | N/A | $325K | N/A | $255K | N/A | $15K |
| Operating Income | -$1.1M-432.2% | -$215K | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $1.5M+707.4% | $183K | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $1K | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.9M-141.7% | -$766K | N/A | -$69K | N/A | $1.1M | N/A | -$15K |
| EPS (Diluted) | $-0.04 | $-0.01 | N/A | N/A | N/A | N/A | N/A | N/A |
ASBPW Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.4M+1523.9% | $148K-99.3% | $20.0M+0.4% | $19.9M-93.4% | $300.2M+0.8% | $297.8M+101474.3% | $293K | N/A |
| Current Assets | $2.4M+1523.9% | $148K+82.2% | $81K-67.9% | $253K-76.9% | $1.1M-4.3% | $1.1M+291.0% | $293K | N/A |
| Cash & Equivalents | $1.9M+53527.1% | $4K-67.5% | $11K+3890.7% | $280-99.9% | $497K-6.7% | $533K | N/A | N/A |
| Inventory | $35K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $13.9M+721.7% | $1.7M-91.8% | $20.5M+2.6% | $20.0M-93.6% | $310.1M+0.9% | $307.5M+104586.9% | $294K | N/A |
| Current Liabilities | $13.9M+721.1% | $1.7M+318.5% | $403K+27.5% | $316K+4.3% | $303K+60.7% | $189K-35.7% | $294K | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$11.5M-644.6% | -$1.5M-215.7% | -$488K-674.9% | -$63K+99.4% | -$9.9M-3.3% | -$9.6M-2025978.1% | -$475-269.6% | $280 |
| Retained Earnings | -$22.6M-712.0% | -$2.8M+75.4% | -$11.3M-3.8% | -$10.9M-9.4% | -$9.9M-3.3% | -$9.6M-37680.5% | -$25K | N/A |
ASBPW Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M+15.7% | -$1.3M-739.0% | -$156K-25.0% | -$125K-248.3% | -$36K+23.1% | -$47K-80.2% | -$26K+85.8% | -$182K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $0 | $0-100.0% | $633K | $0 | $0 | N/A | $166K |
| Financing Cash Flow | $2.8M+122.8% | -$12.5M-8105.7% | $156K+124.6% | -$633K | $0 | $0-100.0% | $26K-85.8% | $182K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $0 | $0-100.0% | $633K | N/A | N/A | N/A | N/A |
ASBPW Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -59015.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -95337.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | 692.1% | N/A | N/A | N/A | N/A |
| Return on Assets | -77.0%+440.4pp | -517.4% | N/A | -0.4% | N/A | 0.4% | N/A | N/A |
| Current Ratio | 0.17+0.1 | 0.09-0.1 | 0.20-0.6 | 0.80-2.8 | 3.62-2.5 | 6.08+5.1 | 1.00 | N/A |
| Debt-to-Equity | -1.21-0.1 | -1.10+40.9 | -41.96+275.0 | -317.01-285.8 | -31.21+0.7 | -31.95+586.4 | -618.31 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Aspire Biopharma Holdings Inc profitable?
No, Aspire Biopharma Holdings Inc (ASBPW) reported a net income of -$12.5M in fiscal year 2024.
What is Aspire Biopharma Holdings Inc's operating cash flow?
Aspire Biopharma Holdings Inc (ASBPW) generated -$2.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Aspire Biopharma Holdings Inc's total assets?
Aspire Biopharma Holdings Inc (ASBPW) had $148K in total assets as of fiscal year 2024, including both current and long-term assets.
Does Aspire Biopharma Holdings Inc buy back shares?
Yes, Aspire Biopharma Holdings Inc (ASBPW) spent $13.8M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Aspire Biopharma Holdings Inc have outstanding?
Aspire Biopharma Holdings Inc (ASBPW) had 28M shares outstanding as of fiscal year 2024.
What is Aspire Biopharma Holdings Inc's current ratio?
Aspire Biopharma Holdings Inc (ASBPW) had a current ratio of 0.09 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Aspire Biopharma Holdings Inc's debt-to-equity ratio?
Aspire Biopharma Holdings Inc (ASBPW) had a debt-to-equity ratio of -1.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aspire Biopharma Holdings Inc's return on assets (ROA)?
Aspire Biopharma Holdings Inc (ASBPW) had a return on assets of -8471.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Aspire Biopharma Holdings Inc's cash runway?
Based on fiscal year 2024 data, Aspire Biopharma Holdings Inc (ASBPW) had $4K in cash against an annual operating cash burn of $2.1M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aspire Biopharma Holdings Inc's debt-to-equity ratio negative or unusual?
Aspire Biopharma Holdings Inc (ASBPW) has negative shareholder equity of -$1.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aspire Biopharma Holdings Inc's Piotroski F-Score?
Aspire Biopharma Holdings Inc (ASBPW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aspire Biopharma Holdings Inc's earnings high quality?
Aspire Biopharma Holdings Inc (ASBPW) has an earnings quality ratio of 0.16x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.